NB (notified bodies) lobbying of MCA (UK Medicines Control Agency) on combination product reviews pays off
This article was originally published in Clinica
Complaints from notified bodies (NBs) in the UK that the Medicines Control Agency takes too long in its review of drug/device combination products have been acknowledged by the agency. The NBs had said that what they saw as the MCA's difficulty in processing straightforward assessments was upsetting their clients' launch strategies. The MCA last week told Clinica that it will address this reputation for being slow in assessing products that combine device and medicinal elements.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.